FiercePharma7h
After Sanofi's first-line myeloma nod, J&J strikes back with new tranche of Darzalex data
Following the FDA's green light for a combo regimen of Sanofi’s Sarclisa in patients with newly diagnosed multiple myeloma ...
FiercePharma7d
Sanofi breaks into first-line multiple myeloma with FDA approval for Sarclisa
Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated ...
Sanofi's Sarclisa Gets FDA Nod for Expanded Use in Multiple Myeloma
This latest FDA decision marks the first approval for SNY's Sarclisa as a first-line treatment for multiple myeloma patients.
Sanofi's Sarclisa Secures FDA Approval For First-Line Multiple Myeloma, Marking Its Third US Approval
Sarclisa (siltuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first-line treatment option ...
pharmaphorum4d
Sanofi's Sarclisa gets one up on rival Darzalex in myeloma
The FDA has approved Sarclisa (isatuximab) as a first-line therapy for blood cancer multiple myeloma as a combination regimen ...
Benzinga.com4d
Sanofi's Sarclisa Secures FDA Approval For First-Line Multiple Myeloma, Marking Its Third US Approval
VRd alone. At a median follow-up of 59.7 months, the median PFS with the Sarclisa-VRd combination was not reached versus 54.3 months with VRd. On Saturday, the FDA approved Sanofi’s SA SNY ...
The Pharma Letter4d
Sanofi’s Sarclisa gains third FDA approval
The US Food and Drug Administration (FDA) has approved Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first line treatment option for adult patients ...
Sanofi wins US approval for multiple myeloma drug in newly diagnosed patients
Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed ...